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Abstract: Background: Research has demonstrated a strong link between trauma, posttraumatic
stress disorder (PTSD) and substance use disorders (SUDs) in general and cannabis use disorders
in particular. Yet, few studies have examined the impact of cannabis use on treatment outcomes for
individuals with co-occurring PTSD and SUDs. Methods: Participants were 136 individuals who
received cognitive-behavioral therapies for co-occurring PTSD and SUD. Multivariate regressions
were utilized to examine the associations between baseline cannabis use and end-of-treatment
outcomes. Multilevel linear growth models were fit to the data to examine the cross-lagged
associations between weekly cannabis use and weekly PTSD symptom severity and primary
substance use during treatment. Results: There were no significant positive nor negative associations
between baseline cannabis use and end-of-treatment PTSD symptom severity and days of primary
substance use. Cross-lagged models revealed that as cannabis use increased, subsequent primary
substance use decreased and vice versa. Moreover, results revealed a crossover lagged effect, whereby
higher cannabis use was associated with greater PTSD symptom severity early in treatment, but lower
weekly PTSD symptom severity later in treatment. Conclusion: Cannabis use was not associated with
adverse outcomes in end-of-treatment PTSD and primary substance use, suggesting independent
pathways of change. The theoretical and clinical implications of the reciprocal associations between
weekly cannabis use and subsequent PTSD and primary substance use symptoms during treatment
are discussed.
Keywords: trauma; PTSD; cannabis; substance use disorder; treatment outcomes
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1. Introduction
Decades of research have demonstrated a strong link between trauma, PTSD and Substance
Use Disorders (SUDs) in general [1–4] and cannabis use disorders in particular [5]. In one large
sample of veterans seeking treatment for PTSD, 14.6% of participants reported using cannabis
in the previous six months [6], and 14% of individuals with lifetime PTSD reported past-year
cannabis use [7]. In a nationally representative adult sample, lifetime trauma was associated with
greater likelihood of lifetime cannabis use, and results showed a graduated relationship between
the co-occurrence of the two, with less severe cannabis use being related to less severe trauma
exposure [8]. A number of etiological models have been proposed to explain the co-occurrence
of PTSD and substance use, including the “self-medication” hypothesis, “high risk” hypothesis,
“susceptibility” hypothesis and “shared vulnerability” models [9–14]. The self-medication hypothesis
posits that individuals with PTSD use substances as a way to manage painful affect states [15,16].
Indeed, a substantial portion of individuals with anxiety and/or PTSD reports symptom relief as
a goal of their substance use [17–19]. While the self-medication hypothesis has received the most
clinical attention and empirical support, several other hypotheses may account for the complex
relationships between PTSD and SUD. The high risk hypothesis posits that a substance-using lifestyle
(e.g., illegal procurement of drugs) places the individual at high risk for exposure to traumatic events
and subsequent development of PTSD [12,14]. Relatedly, the susceptibility hypothesis proposes
that chronic substance use impairs one’s neurobiological system, which enhances the likelihood
of developing PTSD after trauma exposure [9,11]. Shared vulnerability models implicate common
cognitive, affective and neurobiological factors (e.g., attentional bias, emotion regulation difficulties
and dysfunction in the hypothalamic-pituitary-adrenal (HPA) axis) in the development of both PTSD
and SUD and their associations [20]. For example, previous research shows that adults with either
PTSD or SUDs exhibit deficits in emotion processing and self-regulation [21,22].
Cannabis is often used concurrently with other substances, with individuals who used cannabis
in the previous six months being more likely than those who do not use cannabis to smoke
cigarettes (33.9% vs. 61.9%), engage in hazardous alcohol use (8.89% vs. 11.54%) and other drug
use (4.1% vs. 23.8%) [6]. In a sample of adolescents, ongoing regular cannabis use was found to
predict the maintenance of other drug use and to be associated with reduced rates of cessation for
high-risk alcohol use and use of all other substances, with the exception of cocaine [23]. The latter
exception was due to lower prevalence and sporadic use of cocaine compared to other drugs in this
sample. A recent prospective study of 34,653 participants found that use of cannabis at baseline was
a significant predictor of the development of a SUD three years later, even after adjusting for other
sociodemographic factors known to contribute to SUDs [24]. Furthermore, use of multiple substances,
often termed polysubstance use, has been associated with elevated risk of psychiatric and physical
health problems, an increased risk of dependence and overdose and poor treatment outcomes [25].
Interestingly, Swift et al. found that although overall as cannabis users age, prevalence of cannabis use
declines, a greater proportion of users become regular users, and the prevalence of other illicit drug
use increases and progresses [23].
Given the widespread utilization of cannabis among those with PTSD, paired with reductions
in the perception of the harmfulness of cannabis, investigations have now begun to explore whether
the utilization of cannabis prior to, during or after treatment is associated with beneficial or adverse
treatment outcomes among those with co-occurring psychiatric and other substance use disorders.
Several studies suggest that cannabis use is associated with PTSD symptom reduction and improved
coping [26,27]. In a study of coping strategies among veterans experiencing PTSD, a subgroup of
participants reported preferring cannabis to other types of substances and experiencing benefits from
cannabis use, including reductions in anxiety and depression and prevention of intrusive thoughts
and memories [28]. A recent literature review on military veterans with PTSD identified several
small studies showing that cannabis and cannabinoid use were associated with reductions in PTSD
symptoms [26]. Evidence suggests the psychoactive properties of cannabis may be helpful in reducing
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anxiety, extinguishing fears and aversive memories, improving depression and enhancing sleep [28,29].
However, chronic cannabis use has been shown to impair fear extinction in preclinical models relevant
to PTSD [30–32].
The benefits of cannabis use with respect to other drugs of abuse are less clear. Several
studies have reported no association between cannabis use and adverse treatment outcomes among
opioid- and cocaine-dependent patients [33–36]. For example, a study of opioid-dependent youth
who received psychosocial treatments plus buprenorphine-naloxone found that cannabis use prior to
treatment onset and concurrent cannabis use were not associated with opioid use over 12 weeks of
treatment [35]. The authors theorized that cannabis may not have had an impact on outcomes because
the buprenorphine-naloxone treatment may have adequately addressed many of the symptoms that
individuals are likely to use cannabis to relieve (e.g., dysphoria and opioid withdrawal symptoms) [35].
Likewise, a retrospective chart review of individuals during the early phase of outpatient treatment
found that cannabis use was associated with fewer days of opioid use and did not negatively impact
the methadone induction process during methadone maintenance treatment [36]. Similar results have
also been found among cocaine-dependent samples. In a sample of cocaine-dependent individuals
seeking treatment, no significant adverse relationships were found between baseline and during
treatment cannabis use and treatment retention and cocaine abstinence, suggesting that cannabis
use and cocaine use were functionally independent [37]. Given the lack of impairment or adverse
outcomes associated with cannabis use, these findings provide support for a harm reduction approach
with regard to concurrent cannabis use.
However, other studies suggest that cannabis use either before entering or after being
discharged from treatment may be associated with adverse treatment outcomes among opioid and
cocaine-dependent patients [38–40]. For example, a prospective study of heroin-abstinent patients
found that cannabis use was a significant predictor of heroin use resumption [40]. A secondary
analysis of two completed clinical trials of treatment for cocaine dependence found an effect of baseline
marijuana use on response to treatment for cocaine dependence; specifically, more days of marijuana
use at baseline predicted lower treatment effectiveness (cocaine-negative urines) among those receiving
levodopa/carbidopa, but not in the placebo condition [39]. The authors speculated that higher baseline
marijuana use may be a proxy for cocaine severity. The counter argument that concurrent marijuana use
can lead to negative outcomes on other substances proposes that cannabis use may activate the reward
systems in the brain associated with alcohol, opioids and cocaine, leading to use or reinstatement of
these other substances. These studies further suggest that cannabis use may not be as harmless as
perceived and, thus, clinicians should actively assess for and incorporate cannabis use treatment in
their client’s aftercare plan.
Despite mixed findings, the majority of studies reported were conducted with predominantly
young, male, Caucasian or veteran samples receiving primarily medication-assisted treatments; thus,
it remains unclear whether the findings are generalizable to other subgroups of populations. Moreover,
none of the studies to date have examined the impact of cannabis use on treatment outcomes in a
dually-diagnosed sample with co-occurring PTSD and substance use disorders. Additionally, very few
studies have examined the effect of cannabis use on PTSD or primary substance use severity during
treatment. The present study thus sought to extend prior findings by examining whether cannabis
use at baseline and weekly during treatment had an impact on in-treatment and end-of-treatment
PTSD symptom severity and primary substance use among a treatment-seeking dually-diagnosed
population. Given the extant literature on the link between cannabis use and PTSD symptoms, we
hypothesized that baseline and in-treatment cannabis use would be significantly associated with
in-treatment and end-of-treatment PTSD symptom severity. Given the mixed findings in the literature
on the impact of cannabis use on other substance use outcomes and the limited data on the effects
of weekly cannabis use on in-treatment SUD symptomatology, we examined these associations in an
exploratory fashion.
J. Clin. Med. 2017, 6, 14 4 of 15
2. Experimental Section
2.1. Participants
Data for these analyses were derived from two recently-completed clinical trials that tested
combined (behavioral and medication) and integrated cognitive-behavioral treatments for co-occurring
PTSD and substance use disorders. Trial 1 compared Seeking Safety + Sertraline (SS + S) to Seeking
Safety + Placebo (SS + P; see Hien et al. [41] for complete details on the procedures). Trial 2 compared
Concurrent treatment with Prolonged Exposure therapy (COPE), Relapse Prevention Therapy (RPT)
and an Active Monitoring Control Group (AMCG; see Ruglass et al. [42] for complete details on the
procedures). Participants were randomly assigned to each treatment condition. Ethical approval
was obtained for each of the clinical trials (Clinical Trials Registration: clinicaltrials.gov Identifier:
NCT00262223 and NCT01365247) from which these data were drawn. All participants signed written
informed consents approved by the institutional review board. Only participants who received active
cognitive-behavioral treatments were included in these analyses. Participants who were randomized to
the AMCG were excluded because they did not receive a cognitive-behavioral treatment intervention.
We also excluded participants whose primary substance use disorder was cannabis use disorder (n = 9),
since our primary question pertained to the impact of cannabis use on other primary substance use
disorders. Of the 136 participants included in this analysis (out of 179), 32 participants used cannabis
in the seven days prior to baseline and were included in the cannabis use group. The mean age of
cannabis users was 41.63 years (SD = 9.38); approximately 66% were male; and average years of
education were 13.08 (SD = 1.08). Nonusers had a mean age of 44 years old (SD = 9.18); approximately
42% were males; and they completed 13.28 years of education (SD = 2.52), on average. There were no
significant differences in age (t = 1.273, p = 0.205), race/ethnicity distributions (χ2 = 5.12, p = 0.163),
level of education (t = 0.426, p = 0.671) and level of employment (χ2 = 5.12, p = 0.402) between the
cannabis users and nonusers. The cannabis user group was composed of significantly more males
than nonusers (χ2 = 5.33, p = 0.021) and was more likely to have a cocaine use disorder than nonusers
(χ2 = 4.686, p = 0.030). Nonusers were more like to have an alcohol use disorder compared to cannabis
users (χ2 = 7.847, p = 0.005). See Table 1 for a summary of participants’ characteristics by cannabis use.
Table 1. Participants’ characteristics by cannabis use. SUD, Substance Use Disorder.
Variables
Non-Users
(n = 104)
Cannabis
Users (n = 32) Statistics
M (SD) or %
Age 44 (9.18) 41.63 (9.38) t = 1.273, p = 0.205
Gender (Male %) 42% (n = 44) 66% (n = 21) χ2 = 5.33, p = 0.021
Education 13.28 (2.52) 13.08 (1.88) t = 0.426, p = 0.671
Employment in
the Past 3 Years *
% Employed 69.23% (n = 72) 78.13% (n = 25)
χ2 = 5.12, p = 0.402% Unemployed 30.77% (n = 32) 21.87% (n = 7)
Race/Ethnicity †
% White 21.87 (n = 21) 12.5 (n = 4)
χ2 = 5.12, p = 0.163
% Black 59.38 (n = 57) 56.25 (n = 18)
% Hispanic 12.5 (n = 12) 28.12 (n = 9)
% Other (i.e., Native American) 6.25 (n = 6) 3.125 (n = 1)
Cocaine Use Disorder (% Yes) † 37.5 (n = 36) 59.37 (n = 19) χ2 = 4.686, p = 0.030
Alcohol Use Disorder (% Yes) † 94.79 (n = 91) 78.13 (n = 25) χ2 = 7.847, p = 0.005
Other SUD (Opioid, Hallucinogen; % Yes) † 5.2 (n = 5) 6.25 (n = 2) χ2 = 3.403, p = 0.334
* Employed included people that reported working full time or part time. Unemployed included people who
reported being students, retired or unemployed. † The non-user group had missing data for 8 people. The results
are reported based on a sample of 96 people for the non-user group.
2.2. Cognitive-Behavioral Interventions
Trial 1: Seeking Safety (SS) [43] is a manualized 12-week intervention, which applies
cognitive-behavioral strategies to the goals of attaining abstinence from substances and decreasing
PTSD. It was delivered in a 12-session, 60-min weekly individual format by four experienced (Ph.D. or
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licensed clinical social worker (LCSW) level) research therapists who underwent rigorous training in
the Seeking Safety protocol. Participants had up to 14 weeks to complete all 12 sessions. The content of
each session was structured to provide a theme relevant to both substance use disorders and PTSD, and
a specific cognitive-behavioral therapy (CBT) skill to learn. Medication: Matching capsules contained
sertraline or placebo, as well as riboflavin to assess medication adherence. Compliance was also
monitored by pill count. Participants receiving sertraline started on 50 mg daily and titrated up to
200 mg daily over a 2-week period. Participants continued on their full sertraline dose until the
end of the trial and were tapered after unblinding. Responders were offered the option to remain
on medication.
Trial 2: Concurrent treatment with Prolonged Exposure (COPE) is a 12-week intervention that
integrates the empirically-supported models of prolonged exposure for PTSD [44] and RPT for
SUD [45,46]. Participants had up to 14 weeks for treatment completion. Sessions 1 to 3 focused
on goal-setting, psychoeducation and cognitive-behavioral strategies. To address behavioral avoidance
and fear associated with trauma memories, in vivo and imaginal exposures began in Sessions 4 and 5,
respectively, and continued until Session 11. Relapse prevention strategies were integrated with the
prolonged exposure sessions during each 90-min session. Participants recorded progress of exposure
exercises, substance use cravings and use of coping skills. Relapse Prevention Therapy (RPT) [45,46]
is a cognitive-behavioral SUD intervention that focuses on coping strategies to effectively manage
situations that increase the risk of relapse. Psychoeducation, role-playing and active problem-solving
exercises are combined with at-home assignments and geared towards increasing participants’
self-efficacy in preventing relapse.
2.3. Measures
Demographics: In both trials: age, sex, race/ethnicity, education, marital status, employment
pattern and income were collected during the baseline interview.
Psychiatric and alcohol/substance use disorder diagnoses: In both trials, the Structured Clinical
Interview for DSM-IV for Axis I Disorders (SCID-I) [47] was administered at baseline and follow-ups
to assess current Alcohol Use Disorder (AUD) and Substance Use Disorder (SUD) diagnoses, age of
AUD/SUD onset and the presence of any other current or past anxiety, mood or psychotic disorders.
Axis II (personality) disorders were not assessed. AUD/SUD diagnoses were considered current if
diagnostic criteria were met in the prior six months. The SCID-I has demonstrated high interrater
reliability [47].
PTSD symptom severity: In both trials, the Clinician-Administered PTSD Scale (CAPS) [48] was
used at baseline and follow-ups to measure symptom severity in the previous 30 days. The scale
consists of the Re-Experiencing, Avoidance/Numbing and Hyperarousal symptom cluster subscales.
The frequency and intensity scores for each symptom cluster subscale are summed to obtain an overall
total scale score. The CAPS total scores ranges from 0 to 136. Higher scores indicate greater severity.
Clinical assessors received formal training in administering the CAPS. The Modified PTSD Symptom
Scale Self-Report (MPSS-SR) [49] was used weekly during treatment to assess self-reported symptom
severity in the previous 7 days. Although the instruments have different ranges, both yield a total
score comprised of the sum of frequency and intensity ratings of each of the 17 DSM-IV-TR PTSD
symptoms. Psychometric studies of the MPSS-SR with similar comorbid PTSD + SUD treatment
samples demonstrated its high concurrent validity with the CAPS and suggest that it is a reliable tool
for monitoring PTSD symptoms [50].
Substance use: In Trial 1, The Timeline Follow-Back (TLFB) [51] was used to assess alcohol use
patterns at baseline, weekly during the trial and all follow-ups. Participants retrospectively estimated
their daily alcohol consumption in the previous 30 days with a detailed calendar to help orient
them toward patterns in their drinking and specific episodes of erratic or binge drinking. TLFB has
demonstrated good reliability as an instrument for the estimation of daily alcohol consumption [52].
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In Trial 2, primary SUD diagnosis was based on a number of dependence criteria from the SCID-I.
The Addiction Severity Index-Lite (ASI-Lite) [53,54], a semi-structured clinical interview, was used
to assess the frequency of primary substance use in the previous 30 days at baseline and follow-ups.
The ASI-lite had demonstrated good reliability and validity as a measure of the frequency of substance
use and associated consequences [54].
In both trials, the Substance Use Inventory (SUI) [55] was used to assess self-reported frequency
of days of cannabis use in the previous 7 days at baseline, weekly during the trial and all follow-ups.
2.4. Statistical Analyses
Chi-square tests for categorical variables and independent sample t-tests for continuous variables
were used to compare cannabis users and nonusers on baseline sociodemographic variables. Bivariate
correlations were utilized to assess the associations between baseline frequency of cannabis use, age,
end-of-treatment PTSD symptom severity and days of primary substance use. A series of multivariate
regression analyses was conducted to determine whether frequency of marijuana use at baseline
predicted end-of-treatment response on two dimensions (PTSD symptom severity (as measured by
the CAPS) and days of primary substance use (as measured by ASI and TLFB)). End-of-treatment
PTSD symptom severity and days of primary substance use were regressed independently on the
frequency of marijuana use while controlling for baseline scores of either PTSD symptom severity
or days of primary substance use, gender and age. All analyses were run using bootstrap sampling
(1000 bootstrap draws) in order to reduce the chances of a confirmation of null findings due to Type I
error related to sample size.
Several models were specified in a generalized multilevel framework using Stata Version 14 [56]
to examine the cross-lagged impact of cannabis use and primary substance use, as well as the impact
of lagged PTSD symptom severity and the impact of lagged cannabis and primary substance use on
PTSD symptom severity. These models take advantage of the weekly treatment data, while accounting
for nesting (time nested within individuals). For the cross-lagged model, a two-level, multivariate
model was specified with the following Equation (1):
Yijd = (exp(β0ia + β1ia(week− 2)ij + β2ia(cannabis use)ij−1
+β3ia(cannabis use)ij−1 x(week− 2)ij + β2ia(PTSD)ij−1
+ β2ia(PTSD)ij−1 x(week− 2)ij + εij)) + (exp(β0ib
+ β1ib(week− 2)ij + β2ib(primary substance use)ij−1
+ β3ia(primary substance use)ij−1 x(week− 2)ij + β2ia(PTSD)ij−1
+ β2ia(PTSD)ij−1 x(week− 2)ij + εij))
(1)
In this equation, the information to the left of the bolded plus sign represents our first dependent
variable, primary substance use, which is denoted by the subscript a, while the information to the
right of the plus sign represents our second dependent variable, cannabis use, which is denoted by
the subscript b. To model the impact of lagged variables (i.e., weekly cannabis use, weekly primary
substance use, weekly PTSD symptom severity), the variables were lagged by one time point, which is
seen in the above equation by the subscript j − 1. Given that both cannabis use and primary substance
use were lagged in the model, time itself was centered at Week 2 of treatment so that the predicted
intercept (i.e., when x = 0) for each variable would be meaningful.
When we were examining the impact of lagged weekly cannabis and primary substance use on
PTSD symptoms, we were unable to model all of the variables as outcomes simultaneously, as we did
for primary substance use and cannabis use, because of the difference in scales of the substance use
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variables and the PTSD symptom severity [57]. Therefore, a two-level, univariate model was specified
in this case with the following Equation (2):
PTSDij = (exp(β0ia + β1ia(week− 2)ij + β2ia(cannabis use)ij−1
+β3ia(cannabis use)ij−1 x(week− 2)ij
+β2ib(primary substance use)ij−1
+β3ia(primary substance use)ij−1 x(week− 2)ij
(2)
Given that both primary substance use and cannabis use were significantly right skewed and there
was evidence of overdispersion, a negative binomial family distribution and a log link function were
used for all models in which substance use was the outcome. When PTSD symptom severity was the
outcome, a normal distribution was specified. For both models, the unadjusted model controlled only
for time, while sex and age (mean centered) were included as covariates in adjusted models. To present
the most parsimonious model, the final model presented includes only significant predictors.
3. Results
Table 2 shows the zero-order correlations between baseline days of cannabis use and
sociodemographic and outcome variables. The frequency of cannabis use was significantly positively
correlated with days of urge, craving or desire to use cannabis (r = 0.84, p < 0.01). There were no
significant correlations between baseline days of cannabis use and end-of-treatment PTSD symptom
severity or days of primary substance use.
Multivariate regressions with bootstrapping further revealed that baseline days of cannabis use
was not a significant predictor of end of treatment PTSD symptom severity (β = 0.11; t = 1.04, p = 0.30)
or end-of-treatment days of primary substance use (β = 0.25; t = 0.20, p = 0.84), indicating that cannabis
use was not associated with either positive or negative response at end-of-treatment in either domain.
Neither gender, nor age accounted for a significant amount of variance in end-of-treatment PTSD
symptom severity or days of primary substance use (p > 0.05). Only baseline PTSD symptom severity
accounted for a significant proportion of variance in the end-of-treatment PTSD symptom severity
(β = 0.35; t = 3.58, p < 0.01). The overall model fit for predicting end-of-treatment PTSD symptom
severity was R2 = 0.14 and for end-of-treatment days of primary substance use was R2 = 0.04.
A multilevel linear growth model was fit to the data to examine the cross-lagged associations
between weekly cannabis and primary substance use throughout the 12 weeks of treatment. Although
both outcomes were run simultaneously, both unadjusted and adjusted model results are displayed
in two tables (Tables 3 and 4) to increase clarity. In the unadjusted model, results indicated that
individual’s weekly primary substance use decreased significantly during treatment (incident rate
ratio (IRR) = 0.91, 95% CI (0.87, 0.95), p < 0.001), while there was a trend for a decrease in weekly
cannabis use (IRR = 0.90, 95% CI (0.81, 1.00), p = 0.071). There was evidence of a cross-lagged
association for both weekly cannabis (IRR = 0.74, 95% CI (0.67, 0.80), p < 0.001) and primary substance
use (IRR = 0.83, 95% CI (0.74, 0.93), p = 0.002), both indicating that as one substance increased, the other
substance decreased. Lagged PTSD symptom severity was not significantly associated with either
weekly primary substance or cannabis use (p = 0.337 and 0.746, respectively) and none of the lagged
predictors (i.e., weekly cannabis use, weekly primary substance use, PTSD symptom severity) had a
significant interaction with time. After adjusting for age and sex, results indicated that both weekly
primary substance use (IRR = 0.91, 95% CI (0.89, 0.93), p < 0.001) and weekly cannabis use (IRR = 0.91,
95% CI (0.86, 0.96), p < 0.001) significantly decreased during treatment. Further, the cross-lagged
associations between weekly cannabis use and weekly primary substance use were largely unchanged.
Specifically, a one-unit increase in lagged weekly cannabis use was associated with 26% lower weekly
primary substance use, while a one-unit increase in lagged primary substance use was associated with
14% lower weekly cannabis use.
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Table 2. Correlations between study variables.
Variables Age Education Days ofCannabis Use †
Days of Urge, Desire or
Craving for Cannabis †
Baseline Primary
Substance Use ‡
End-of-Treatment
Primary Substance Use ‡
Baseline
CAPS 1
End-of-Treatment
CAPS 1
Age 1 0.101 −0.009 −0.031 −0.011 −0.077 0.006 −0.051
Education 1 −0.114 −0.194 −0.091 0.129 −0.022 −0.001
Days of cannabis use † 1 0.844 ** 0.007 0.004 0.069 0.157
Days of urge, desire or craving for cannabis † 1 0.073 −0.028 0.113 0.081
Baseline Primary Substance use ‡ 1 0.049 0.094 −0.016
End-of-treatment Primary Substance use ‡ 1 0.140 0.370 **
Baseline CAPS 1 0.377 **
End-of-treatment CAPS 1
1 CAPS = Clinician-Administered PTSD Scale; ** p < 0.01, results are based on 1000 bootstrap samples; ‡ number of days of primary substance use in past 30 days; † number of days of use
in the past 7 days.
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Table 3. Exponentiated regression coefficients for models examining the association of cross-lagged
weekly cannabis use on primary substance use.
Predictors Unadjusted ModelIRR (95% CI)
Final Adjusted Model
IRR (95% CI)
Status at Week 2 of Treatment:
Intercept 7.81 (5.05, 12.07) *** 7.12 (5.32, 9.53) ***
Sex (female) – NS
Age – 0.96 (0.93, 0.98) ***
Lagged Cannabis Use 0.74 (0.67, 0.80) *** 0.74 (0.69, 0.79) ***
Lagged PTSD 1.00 (1.00, 1.01) NS
Rate of Change:
Time (linear) 0.91 (0.87, 0.95) *** 0.91 (0.89, 0.93)
Lagged Cannabis Use X Time (linear) 0.98 (0.96, 1.00) NS
Lagged PTSD X Time (linear) 1.00 (1.00, 1.00) NS
Note: This model was specified with a negative binomial distribution. Negative binomial regression coefficients
are expected differences in log counts. All coefficients presented here are exponentiated. When exponentiated, the
intercept represents an expected count of days of primary substance use (when time = 0), and the slope represents a
ratio of expected counts or an incident rate ratio. All predictors are also interpreted as ratios of expected counts
or incident rate ratios (IRRs). For example, the IRR of 0.74 for lagged cannabis use is interpreted to mean that a
one-unit change in lagged cannabis use was associated with a 26% lower expected count of primary substance use
(when all other predictors were held constant). Sex was coded dichotomously with males equal to 0, while age was
mean centered. *** p < 0.001.
Table 4. Exponentiated regression coefficients for models examining the association of cross-lagged
primary substance use on weekly cannabis use.
Variables Unadjusted ModelIRR (95% CI)
Final Adjusted Model
IRR (95% CI)
Status at Week 2 of Treatment:
Intercept 1.71 (0.85, 3.45) 2.25 (1.42, 3.53) ***
Sex (female) – 0.23 (0.15, 0.34) ***
Age – 0.92 (0.89, 0.95) ***
Lagged Primary Substance Use 0.83 (0.74, 0.93) ** 0.86 (0.80, 0.93) ***
Lagged PTSD 1.00 (1.00, 1.01) NS
Rate of Change:
Time (linear) 0.90 (0.81, 1.00) 0.91 (0.86, 0.96) ***
Lagged Primary Substance use X Time (linear) 1.00 (0.97, 1.02) NS
Lagged PTSD X Time 1.00 (1.00, 1.00) NS
Note: This model was specified with a negative binomial distribution. Negative binomial regression coefficients
are expected differences in log counts. All coefficients presented here are exponentiated. When exponentiated, the
intercept represents an expected count of days of cannabis use (when time = 0), and the slope represents a ratio of
expected counts or an incident rate ratio. All predictors are also interpreted as ratios of expected counts or incident
rate ratios (IRRs). For example, the IRR of 0.86 for lagged primary substance use is interpreted to mean that a
one-unit change in lagged primary substance use was associated with a 14% lower expected count of cannabis use
(when all other predictors were held constant). Sex was coded dichotomously with males equal to 0, while age was
mean centered. ** p < 0.01; *** p < 0.001.
A second multilevel linear growth model was fit to the data to examine the associations between
lagged weekly cannabis and primary substance use on PTSD symptom severity throughout the
12 weeks of treatment. Both unadjusted and adjusted results are displayed in Table 5. In the unadjusted
results (β = −1.60, 95% CI (−2.06, −1.13), p < 0.001), PTSD symptom severity decreased significantly
during treatment. However, neither lagged weekly cannabis, nor primary substance use was associated
with weekly PTSD symptom severity (ps = 0.128 and 0.901, respectively). In addition, lagged weekly
primary substance use did not interact with time in the prediction of PTSD symptom severity scores
(p = 0.902). However, the interaction between lagged weekly cannabis use and time was significant
(β = −0.23, 95% CI (−0.43, −0.02), p = 0.029). After adjusting for covariates, results remained largely
unchanged. The interaction between lagged weekly cannabis use and time was explored (see Figure 1)
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and indicated that there was a crossover effect; although higher weekly lagged cannabis use was
associated with greater PTSD symptom severity early in treatment, later in treatment, higher weekly
lagged cannabis use was associated with lower PTSD symptom severity.
Table 5. Exponentiated regression coefficients for models examining the impact of lagged weekly
cannabis use and primary substance use on PTSD symptom severity.
Variables Unadjusted Model Adjusted Model
Status at Week 2 of Treatment:
Intercept 45.41 (39.85, 50.98) *** 45.71 (40.65, 50.77) ***
Lagged Cannabis Use 1.04 (−0.30, 2.37) NS
Lagged Primary Substance Use −0.06 (−1.05, 0.93) 0.98 (−0.25, 2.21)
Sex (female) – NS
Age – NS
Rate of Change:
Time (linear) −1.60 (−2.06, −1.13) *** −1.41 (−1.74, −1.07) ***
Lagged Cannabis Use X Time (linear) −0.23 (−0.43, −0.02) * −0.23 (−0.44, −0.03) *
Lagged Primary Substance Use X Time (linear) 0.01 (−0.15, 0.17) NS
Note: This model was specified with a normal distribution. The intercept represents the expected value of PTSD
symptom severity when all other predictors are held constant at 0, while the slope represents the expected difference
in PTSD symptom severity given a one-unit change in time (all other variables held constant). All predictors are
interpreted similarly to the slope and represent the expected difference due to a one-unit change in the predictor
(all other predictors held constant). Sex was coded dichotomously with males equal to 0, while age was mean
centered. * p < 0.05; *** p < 0.001.
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Figure  1. Figure  showing  the  adjusted  results of weekly  lagged  cannabis use  and weekly  lagged 
cannabis use x time, predicting weekly PTSD symptom severity scores. The x‐axis represents the time 
from  week  2  of  treatment  to  week  12  of  treatment  (week  1  is  not  represented  because  the 
independent variable is lagged one time‐point), while the y‐axis represents the predicted score on the 
Figure 1. Figure sho ing the adjusted results of eekly lagged cannabis use and eekly lagged
cannabis use x ti e, predicting eekly PTS sy pto severity scores. The x-axis represents the ti e
fro week 2 of treatment to week 12 of treatment (week 1 is not represented because the independent
variable is lagged one time-point), while the y-axis represents the predicted score on the PTSD symptom
severity measure. Results show a crossover effect, whereby higher weekly lagged cannabis use was
associated with greater weekly PTSD symptom severity early in treatment, but lower weekly PTSD
symptom severity later in treatment.
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4. Discussion
This study examined the associations between cannabis use and in-treatment and end-of-treatment
PTSD symptom severity and frequency of primary substance use among a sample of adults
with co-occurring PTSD and substance use disorders who received cognitive-behavioral therapy.
Approximately 24% of the sample reported cannabis use prior to treatment, and more men were
cannabis users than non-users. Cannabis users were more likely to have comorbid cocaine use
disorders, whereas nonusers were more likely to have an alcohol use disorder. This finding is consistent
with prior studies showing that approximately 60% to 90% of those with cocaine use disorder also
use cannabis [58]. Analyses revealed that baseline cannabis use was neither negatively, nor positively
associated with end-of-treatment PTSD symptom severity. In contrast to a line of studies showing
that individuals with PTSD, particularly those who struggle with hyperarousal and sleep problems,
may be more likely to use cannabis to cope with their traumatic stress symptoms [19,59], cannabis use
was independent of symptom outcomes at end-of-treatment across participants undergoing cognitive
behavioral therapy for PTSD and SUD. Our results also revealed a cross-over effect when examining
the lagged association between weekly cannabis use and weekly PTSD symptoms during 12 weeks of
treatment. Higher cannabis use was associated with higher PTSD symptom severity early in treatment,
but lower PTSD symptom severity later in treatment. It is possible that early in treatment, cannabis
may be used frequently in order to ameliorate high levels of PTSD symptoms. However, later in
treatment, high cannabis use may interact synergistically with psychological treatment to reduce PTSD
symptoms. The present study, however, was not able to examine the interaction between cannabis use
and treatment; thus, these hypotheses are speculative. Future studies are recommended to replicate
and tease apart the mechanisms of these findings.
The lack of association between baseline cannabis use and end-of-treatment frequency of primary
substance use is consistent with a set of research suggesting cannabis use is independent of other
substance use, particularly after treatment [33–36]. Importantly, findings from the present study
further suggest that cannabis use before treatment is not associated with adverse PTSD outcomes in
this sample. One of the clinically-salient questions in treatment of concurrent substance use involves
what position clinicians should take regarding concurrent use of cannabis among other illicit substance
users. Abstinence model perspectives would argue that any use of any substance type in ongoing
treatment would be discouraged. In contrast, harm reduction models would identify reductions
in drug use severity measured in metrics involving both type of substance used (i.e., more or less
public health impact) and also the amount of use by type of substance as key indicators of treatment
improvement [60]. Findings from our cross-lagged analyses bear on these perspectives. Analyses
revealed that as weekly cannabis use increased, subsequent weekly primary substance use decreased
and vice versa. These findings contrast with studies showing that ongoing regular cannabis use was a
significant predictor of subsequent increases in illicit drug use [23]. It is possible that, in this sample,
the psychoactive properties of cannabis reduce the likelihood that participants will utilize their primary
substance of choice. Alternatively, increases in weekly primary drug of choice may decrease the desire
for cannabis. Regardless, from a harm reduction perspective, the utilization of cannabis instead of
other illicit substances and alcohol may be associated with less harmful consequences and, thus, may
be seen as a more acceptable intermediate outcome.
Several limitations should be noted. The lack of association between baseline cannabis use and
end-of-treatment outcomes should be interpreted with caution given the small sample size of cannabis
users. Moreover, we utilized frequency/days of cannabis use instead of quantity or severity of use,
which could have been more sensitive to detecting associations among these variables. Further, because
we utilized the global category of primary substance use, we were not able to tease apart the specific
associations between cannabis and specific types of drugs (e.g., cocaine, alcohol or heroin). Self-report
measures of substance use bring inherent biases related to recall and social desirability. Finally, since
the study was not originally designed to test the impact of cannabis use on treatment outcomes, these
post-hoc subgroup analyses may suffer from selection bias.
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Despite these limitations, this is one of the first studies to examine the impact of cannabis
use in a racially-/ethnically-diverse sample of participants receiving cognitive behavioral therapies
for co-occurring PTSD and substance use disorders. In addition to documenting moderate rates of
cannabis use among those with other primary substance use disorders, these findings provide evidence
in support of a harm reduction perspective in the treatment of addictions with PTSD. First, our
findings demonstrated that baseline cannabis use was not associated with end-of-treatment outcomes,
suggesting independent pathways of change. Second, cross-lagged predictive models examining
the impact of previous week cannabis use on subsequent primary substance use revealed an inverse
relationship showing that increasing cannabis use was actually associated with lowering primary
substance use. Conversely, increasing primary substance use in the previous week was associated with
lowering cannabis use the following week. Moreover, findings revealed a cross-over effect, whereby
higher cannabis use was related to higher PTSD symptom severity early in treatment, but lower
PTSD symptom severity later in treatment. Taken as a whole, our findings provide more support in
the controversy that cannabis use (in non-primary cannabis dependence users) is not necessarily an
adverse component to the treatment process for addictions.
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